200 related articles for article (PubMed ID: 23219833)
21. Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma.
Mizutani Y; Matsubara H; Yamamoto K; Nan Li Y; Mikami K; Okihara K; Kawauchi A; Bonavida B; Miki T
Cancer; 2004 Oct; 101(8):1794-802. PubMed ID: 15386310
[TBL] [Abstract][Full Text] [Related]
22. Pathophysiological roles of osteoprotegerin (OPG).
Reid P; Holen I
Eur J Cell Biol; 2009 Jan; 88(1):1-17. PubMed ID: 18707795
[TBL] [Abstract][Full Text] [Related]
23. Osteoprotegrin and the bone homing and colonization potential of breast cancer cells.
Kapoor P; Suva LJ; Welch DR; Donahue HJ
J Cell Biochem; 2008 Jan; 103(1):30-41. PubMed ID: 17471510
[TBL] [Abstract][Full Text] [Related]
24. The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.
Jin K; Park S; Ewton DZ; Friedman E
Cancer Res; 2007 Aug; 67(15):7247-55. PubMed ID: 17671193
[TBL] [Abstract][Full Text] [Related]
25. Aurora B confers cancer cell resistance to TRAIL-induced apoptosis via phosphorylation of survivin.
Yoon MJ; Park SS; Kang YJ; Kim IY; Lee JA; Lee JS; Kim EG; Lee CW; Choi KS
Carcinogenesis; 2012 Mar; 33(3):492-500. PubMed ID: 22159225
[TBL] [Abstract][Full Text] [Related]
26. Regulation of the resistance to TRAIL-induced apoptosis as a new strategy for pancreatic cancer.
Mori T; Doi R; Toyoda E; Koizumi M; Ito D; Kami K; Kida A; Masui T; Kawaguchi Y; Fujimoto K
Surgery; 2005 Jul; 138(1):71-7. PubMed ID: 16003319
[TBL] [Abstract][Full Text] [Related]
27. Expression of receptor activator of nuclear factor kappabeta ligand (RANKL) and tumour necrosis factor related, apoptosis inducing ligand (TRAIL) in breast cancer, and their relations with osteoprotegerin, oestrogen receptor, and clinicopathological variables.
Cross SS; Harrison RF; Balasubramanian SP; Lippitt JM; Evans CA; Reed MW; Holen I
J Clin Pathol; 2006 Jul; 59(7):716-20. PubMed ID: 16489180
[TBL] [Abstract][Full Text] [Related]
28. The osteoprotegerin/tumor necrosis factor related apoptosis-inducing ligand axis in the kidney.
Candido R
Curr Opin Nephrol Hypertens; 2014 Jan; 23(1):69-74. PubMed ID: 24247823
[TBL] [Abstract][Full Text] [Related]
29. Regulation of TRAIL-induced apoptosis by XIAP in pancreatic carcinoma cells.
Vogler M; Dürr K; Jovanovic M; Debatin KM; Fulda S
Oncogene; 2007 Jan; 26(2):248-57. PubMed ID: 16832350
[TBL] [Abstract][Full Text] [Related]
30. Expression and functional activity of osteoprotegerin in human malignant gliomas.
Naumann U; Wick W; Beschorner R; Meyermann R; Weller M
Acta Neuropathol; 2004 Jan; 107(1):17-22. PubMed ID: 14504888
[TBL] [Abstract][Full Text] [Related]
31. Influence of casein kinase II in tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human rhabdomyosarcoma cells.
Izeradjene K; Douglas L; Delaney A; Houghton JA
Clin Cancer Res; 2004 Oct; 10(19):6650-60. PubMed ID: 15475455
[TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin in prostate cancer bone metastasis.
Corey E; Brown LG; Kiefer JA; Quinn JE; Pitts TE; Blair JM; Vessella RL
Cancer Res; 2005 Mar; 65(5):1710-8. PubMed ID: 15753366
[TBL] [Abstract][Full Text] [Related]
33. Effect of the XIAP inhibitor Embelin on TRAIL-induced apoptosis of pancreatic cancer cells.
Mori T; Doi R; Kida A; Nagai K; Kami K; Ito D; Toyoda E; Kawaguchi Y; Uemoto S
J Surg Res; 2007 Oct; 142(2):281-6. PubMed ID: 17640673
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of RIP and c-FLIP enhances TRAIL-induced apoptosis in pancreatic cancer cells.
Wang P; Zhang J; Bellail A; Jiang W; Hugh J; Kneteman NM; Hao C
Cell Signal; 2007 Nov; 19(11):2237-46. PubMed ID: 17693058
[TBL] [Abstract][Full Text] [Related]
35. Combined silencing of K-ras and Akt2 oncogenes achieves synergistic effects in inhibiting pancreatic cancer cell growth in vitro and in vivo.
Shi XH; Liang ZY; Ren XY; Liu TH
Cancer Gene Ther; 2009 Mar; 16(3):227-36. PubMed ID: 18949011
[TBL] [Abstract][Full Text] [Related]
36. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
[TBL] [Abstract][Full Text] [Related]
37. Profiling of chemonaive osteosarcoma and paired-normal cells identifies EBF2 as a mediator of osteoprotegerin inhibition to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis.
Patiño-García A; Zalacain M; Folio C; Zandueta C; Sierrasesúmaga L; San Julián M; Toledo G; De Las Rivas J; Lecanda F
Clin Cancer Res; 2009 Aug; 15(16):5082-91. PubMed ID: 19671856
[TBL] [Abstract][Full Text] [Related]
38. Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death.
Meslin F; Hamaï A; Gao P; Jalil A; Cahuzac N; Chouaib S; Mehrpour M
Cancer Res; 2007 Nov; 67(22):10910-9. PubMed ID: 18006836
[TBL] [Abstract][Full Text] [Related]
39. In vitro modeling of human pancreatic duct epithelial cell transformation defines gene expression changes induced by K-ras oncogenic activation in pancreatic carcinogenesis.
Qian J; Niu J; Li M; Chiao PJ; Tsao MS
Cancer Res; 2005 Jun; 65(12):5045-53. PubMed ID: 15958547
[TBL] [Abstract][Full Text] [Related]
40. Trail down-regulates the release of osteoprotegerin (OPG) by primary stromal cells.
Corallini F; Celeghini C; Rimondi E; di Iasio MG; Gonelli A; Secchiero P; Zauli G
J Cell Physiol; 2011 Sep; 226(9):2279-86. PubMed ID: 21660951
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
